Category: Uncategorized

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Back

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Read More

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Back

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Read More

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Back

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Read More

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Back

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Read More

Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia

Back

Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia

Read More

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Back

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Read More

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Back

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Read More

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Back

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Read More

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders

Back

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders

Read More

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Back

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Read More